Behçet's Disease

Behçet's disease is a rare systemic vasculitis of unknown etiology, first described by the Turkish dermatologist Hulusi Behçet in 1937 as a "triple-symptom complex" of recurrent oral aphthous ulcers, genital ulcers, and ocular inflammation. Now recognized as a multisystem inflammatory disorder affecting blood vessels of all sizes, Behçet's disease is distinguished by its Silk Road geographic distribution — highest prevalence in Turkey, the Middle East, Central Asia, and Japan — and by the absence of a specific autoantibody or definitive laboratory marker, making it a clinical diagnosis. The disease can affect virtually every organ system and carries particular morbidity from posterior uveitis (a leading cause of blindness in young adults in endemic regions), neurological involvement, and large-vessel vasculopathy.

Table of Contents

  1. Overview
  2. Historical Recognition
  3. Pathophysiology and Immunology
  4. Clinical Manifestations
  5. Diagnostic Criteria and Workup
  6. Treatment
  7. Differential Diagnosis
  8. Prognosis and Monitoring
  9. Recent Research and Advances
  10. References
  11. Connections
  12. Featured Videos

Overview

Behçet's disease is a chronic, relapsing-remitting multisystem vasculitis that uniquely affects blood vessels of all calibers — small, medium, and large arteries and veins alike. The classical presentation is the triple-symptom complex: recurrent oral aphthous ulcers, recurrent genital ulcers, and ocular inflammatory disease. These three manifestations, individually common in isolation, become diagnostic in combination and set Behçet's apart from other inflammatory conditions. However, the disease extends far beyond this triad, capable of involving the skin, joints, gastrointestinal tract, cardiovascular system, and central nervous system.

Unlike most autoimmune diseases, Behçet's disease lacks a defining autoantibody. Antinuclear antibodies (ANA), antineutrophil cytoplasmic antibodies (ANCA), anti-double-stranded DNA, and rheumatoid factor are all negative, reflecting a pathogenesis driven more by innate immune dysregulation and T-cell activation than by classical antibody-mediated autoimmunity. This absence of a serological marker makes the diagnosis entirely clinical, based on the International Study Group (ISG) 1990 criteria or the revised International Criteria for Behçet's Disease (ICBD) 2014.

The disease's epidemiology traces what historians call the ancient Silk Road — the trade route connecting East Asia, Central Asia, the Middle East, and the Mediterranean. Turkey has the world's highest prevalence (80–370 per 100,000 population), followed by Iran, Iraq, Saudi Arabia, Israel, Japan, and South Korea. Prevalence drops sharply in Western Europe and North America, where the disease is encountered primarily in immigrants from endemic regions. This geographic clustering, combined with the strong association with HLA-B51 (the most robustly replicated genetic risk factor worldwide), suggests that specific genetic backgrounds in concert with environmental exposures — possibly microbial triggers along ancient trade routes — drive susceptibility.

Young adults in their third and fourth decades are most commonly affected, with a slight male predominance in the highest-prevalence regions. Disease severity is generally worse in young males in endemic areas, who are at greatest risk for the most devastating complications: bilateral blindness from posterior uveitis, cerebral venous sinus thrombosis, pulmonary artery aneurysm rupture, and progressive neurological disability.

Back to Table of Contents

Historical Recognition

The syndrome we now call Behçet's disease has a longer documented history than is commonly appreciated. The ancient Greek physician Hippocrates, writing around the 5th century BCE in his work Epidemics III, described a condition prevalent in Asia Minor characterized by "aphthous ulcers in the mouth, inflammation of the genitals, and watery discharges from the eyes" — an account strikingly consistent with the modern triad. This earliest reference, preserved for over 2,400 years, underscores the disease's deep geographic roots in the Eastern Mediterranean.

The modern clinical history begins in 1931, when Benedict Adamantiades, a Greek ophthalmologist, published a detailed case report in the Annales d'Oculistique describing a patient with recurrent hypopyon uveitis, oral ulcers, and genital ulcers — the complete triad — along with arthritis and vascular involvement. Adamantiades correctly identified the systemic nature of the condition and its vascular component. His contribution is commemorated by the designation Adamantiades-Behçet disease, which is preferred by many European and Greek rheumatologists.

In 1937, Hulusi Behçet, a Turkish dermatologist at Istanbul University, published his landmark paper in Dermatologische Wochenschrift describing three Turkish patients with the recurrent triad of oral aphthous ulcers, genital ulcers, and ocular inflammation (iritis with hypopyon). Behçet proposed the syndrome represented a distinct viral entity and formally named it a "triple-symptom complex." His systematic clinical description, published in German — the dominant language of medicine at the time — brought international attention to the condition and led to the eponym by which it is most widely known. Behçet himself died in 1948, before the disease bearing his name was internationally accepted as a unified entity.

Formal diagnostic criteria were established by the International Study Group for Behçet's Disease in 1990, providing the first standardized framework for epidemiological and clinical research. The ISG 1990 criteria required recurrent oral ulcers (at least three times in a 12-month period) plus at least two of the following: recurrent genital ulcers, characteristic eye lesions, characteristic skin lesions, or a positive pathergy test. These criteria proved highly specific but insufficiently sensitive — many patients with unambiguous Behçet's disease, particularly in non-Middle Eastern populations where pathergy is less prevalent, failed to meet the threshold. The International Criteria for Behçet's Disease (ICBD), revised and published in 2014 by Davatchi and colleagues from 27 countries, introduced a point-based scoring system that improved sensitivity while maintaining acceptable specificity, expanding the diagnostic net to capture more Western patients and those with predominantly neurological or vascular presentations.

Back to Table of Contents

Pathophysiology and Immunology

The etiology of Behçet's disease remains unknown, but extensive research over the past three decades has established immune dysregulation as the central mechanism, with both innate and adaptive immune compartments contributing. The disease is not classified as a classic autoimmune condition (no autoantibody, no complement consumption) nor a pure autoinflammatory condition (T-cell involvement is prominent), but rather occupies a unique immunological niche that bridges these categories.

Neutrophil hyperactivation is a hallmark of Behçet's disease and the basis of one of its most characteristic clinical signs. Neutrophils from patients with Behçet's demonstrate increased spontaneous oxidative burst, enhanced chemotaxis, elevated expression of adhesion molecules, and exaggerated responses to stimuli that cause minimal reaction in healthy controls. This state of priming explains the pathergy phenomenon — the development of a sterile pustule 24–48 hours after a simple needle prick or minor skin trauma — which reflects generalized neutrophilic hyperresponsiveness. Neutrophil extracellular traps (NETs) are increasingly implicated as mediators of vascular endothelial injury in Behçet's vasculitis.

T-cell imbalance is equally central to the immunopathology. The Th1 axis is dominant in active disease, with elevated circulating and tissue levels of IFN-γ, TNF-α, and IL-12. The Th17 axis is also strongly activated, with high serum and synovial IL-17A levels correlating with disease activity, particularly in articular and mucocutaneous manifestations. Critically, regulatory T cells (Tregs) are reduced in number and function during active Behçet's flares, failing to suppress the Th1 and Th17 responses. This regulatory deficit allows sustained inflammatory amplification that is disproportionate to the inciting stimulus.

HLA-B51 is the strongest and most consistently replicated genetic risk factor for Behçet's disease across all ethnic populations, originally identified in Japanese patients in 1973. The specific causal allele is HLA-B*51:01. The relative risk conferred by HLA-B51 is approximately 5–6-fold in Turkish and Japanese populations. HLA-B51 is thought to present one or more peptide antigens — possibly microbial or self-derived — that drive autoreactive CD8+ T-cell responses, though the precise presented peptide(s) have not been definitively identified. Genome-wide association studies (GWAS) have confirmed HLA-B51 and identified additional risk loci including IL-10, IL-23R, ERAP1, CCR1, and KLRB1, pointing to dysregulated cytokine signaling and natural killer cell function as contributory genetic pathways.

Microbial triggers have long been suspected as initiating stimuli that activate the dysregulated immune system in genetically susceptible individuals. Streptococcus sanguis, an oral commensal, has received the most attention: patients with Behçet's disease have higher oral colonization rates, stronger lymphocyte responses to streptococcal antigens, and cross-reactive T-cell responses between streptococcal heat-shock protein (HSP) 65 and human HSP 60, supporting molecular mimicry as a mechanism. Herpes simplex virus type 1 (HSV-1) has also been implicated — HSV-1 DNA has been detected in mucosal lesions and peripheral blood mononuclear cells of some Behçet's patients, and oral antiviral therapy (thalidomide in one study) reduces mucocutaneous recurrences. However, no single microbial trigger has been proven causal, and it is possible that multiple pathogens serve as initiators in a background of genetic susceptibility.

The vasculitis in Behçet's disease is distinctive for simultaneously affecting both arteries and veins of all calibers and for causing both thrombotic occlusion and aneurysmal dilatation — often in the same patient. The venous thromboses of Behçet's disease are driven by inflammation rather than coagulation factor abnormalities, explaining why anticoagulation alone is less effective than immunosuppression in treating them. Pulmonary artery aneurysms, caused by vasculitis of the vasa vasorum of large arteries, represent the most life-threatening vascular complication.

Back to Table of Contents

Clinical Manifestations

Oral ulcers are the most frequent and often the earliest manifestation of Behçet's disease, present in virtually all patients at some point in their course and required by the ISG 1990 criteria. The ulcers are aphthous in character: round or oval, with a well-defined erythematous border and a central gray or yellow pseudomembranous base. They are intensely painful, ranging from 2 mm to over 2 cm in diameter, and appear singly or in crops on the buccal mucosa, gingiva, tongue, palate, and pharynx. By definition, oral ulcers must occur at least three times in a 12-month period to fulfill the ISG diagnostic criterion. Individual ulcers typically heal within 7–14 days without scarring, but recur with high frequency. Their prevalence and frequency make them the hallmark of disease monitoring.

Genital ulcers are less frequent than oral ulcers (present in 60–90% of patients over the disease course) but are more specific for Behçet's disease. In men, they occur predominantly on the scrotum; in women, on the vulva and vaginal mucosa. Unlike oral ulcers, genital ulcers are deeper, more destructive, and frequently leave permanent scars — a finding that, when present, is highly diagnostic. They are also more painful per episode than oral ulcers and may be accompanied by regional lymphadenopathy.

Ocular disease is the most feared manifestation in terms of long-term disability. Posterior uveitis with retinal vasculitis is the most serious ocular complication — inflammation of the retinal vessels causes ischemia, neovascularization, vitreous hemorrhage, epiretinal membrane formation, and ultimately irreversible retinal atrophy with loss of central vision. The classic anterior manifestation is hypopyon uveitis — the accumulation of inflammatory cells forming a visible white layer (hypopyon) in the anterior chamber, which is dramatic on slit-lamp examination but actually less dangerous to long-term vision than posterior involvement. Ocular disease is bilateral in 70–80% of cases. In the pre-treatment era, 25% of Behçet's patients with ocular disease became legally blind within five years. Prompt and aggressive immunosuppression has substantially improved these outcomes.

Skin lesions take several forms. Erythema nodosum — tender, red nodules on the shins representing septal panniculitis — is the most common skin manifestation. Pseudofolliculitis describes pustular lesions resembling folliculitis that appear on the trunk, legs, and face but are not follicle-centered on histology. Papulopustular lesions (acneiform eruptions) are common, particularly in men. The pathergy phenomenon, in which sterile papules or pustules develop 24–48 hours after needle puncture of normal skin, reflects the systemic neutrophilic hyperresponsiveness of the disease. Pathergy is positive in 50–80% of Turkish and Middle Eastern patients but is substantially less prevalent in Japanese patients (10–30%) and Western patients, making it a regionally variable diagnostic finding.

Arthritis in Behçet's disease is typically non-erosive, asymmetric, and oligoarticular, predominantly affecting large joints — knees, ankles, wrists, and elbows. It is seronegative (rheumatoid factor and anti-CCP negative) and causes no joint destruction or deformity. Arthralgia is more common than true synovitis. Sacroiliitis is rare and HLA-B27 association is not a feature, distinguishing Behçet's from classic spondyloarthropathy. Articular flares often coincide with mucocutaneous disease activity.

Vascular disease is a defining feature that distinguishes Behçet's from almost all other inflammatory arthropathies. Venous thrombosis is the most common vascular manifestation: deep vein thrombosis of the lower limbs is the classic presentation, but superficial thrombophlebitis, Budd-Chiari syndrome (hepatic vein thrombosis), superior and inferior vena cava thrombosis, dural venous sinus thrombosis (a cause of intracranial hypertension), and portal vein thrombosis all occur. These thromboses are driven by venous wall inflammation rather than hypercoagulability alone, which has important therapeutic implications — immunosuppression is the primary treatment, with anticoagulation as an adjunct. Arterial involvement, though less common, is more dangerous: pulmonary artery aneurysms present with massive hemoptysis and can be rapidly fatal. Peripheral and visceral arterial aneurysms also occur. Paradoxically, the same patient may have both thrombotic and aneurysmal vascular disease, a combination essentially unique to Behçet's.

Gastrointestinal disease occurs in 10–50% of patients and is particularly prevalent in Japanese and Korean patients compared to Middle Eastern patients. The terminal ileum and cecum are preferentially affected, producing deep, punched-out ulcers that can lead to perforation, fistula formation, or massive bleeding. The distribution and ileocecal predominance overlap with Crohn's disease, but Behçet's GI ulcers are characteristically round and discrete with a "punched-out" appearance on colonoscopy, while Crohn's produces linear ulcers, skip lesions, and transmural inflammation with granuloma formation on biopsy. Distinguishing these two conditions is clinically important because treatment approaches differ.

Neurological disease (neuro-Behçet) affects approximately 5–10% of patients and carries the worst prognosis of any Behçet's manifestation. Two major patterns are recognized. Parenchymal neuro-Behçet involves direct inflammatory infiltration of brain parenchyma, particularly the brainstem, diencephalon, and basal ganglia, producing pyramidal tract signs, behavioral and cognitive change, cerebellar ataxia, and cranial nerve palsies. MRI shows T2/FLAIR hyperintensity in a characteristic brainstem-predominant pattern. This form carries a significant risk of permanent disability and death. Vascular neuro-Behçet involves dural venous sinus thrombosis causing intracranial hypertension with headache, papilledema, and visual obscurations; prognosis is generally better. Aseptic meningitis — acute, self-limited, without parenchymal involvement — also occurs. Cyclosporine, though effective for ocular disease, is relatively contraindicated in patients with or at risk for neuro-Behçet, as it may precipitate or worsen CNS involvement.

Back to Table of Contents

Diagnostic Criteria and Workup

Behçet's disease is a clinical diagnosis — there is no pathognomonic laboratory test, biopsy finding, or imaging feature. The diagnosis requires careful pattern recognition integrating history, physical examination, and the systematic application of validated criteria. The two principal frameworks are the International Study Group (ISG) 1990 criteria and the International Criteria for Behçet's Disease (ICBD) 2014.

ISG 1990 Criteria require recurrent oral ulcers (minor or major aphthous or herpetiform ulcers observed by the physician or patient, recurring at least three times in a 12-month period) as a mandatory criterion, plus at least two of the following four: (1) recurrent genital ulcers (aphthous ulceration or scarring observed by the physician or patient); (2) eye lesions (anterior uveitis, posterior uveitis, cells in the vitreous on slit-lamp examination, or retinal vasculitis observed by an ophthalmologist); (3) skin lesions (erythema nodosum, pseudofolliculitis, papulopustular lesions, or acneiform nodules in post-adolescent patients not on corticosteroids); (4) positive pathergy test (read by a physician at 24–48 hours after intradermal saline or needle puncture). These criteria have sensitivity of 85–91% and specificity of 96% in endemic populations.

ICBD 2014 Criteria use a point-based scoring system that weights ocular lesions and oral and genital ulcers most heavily (2 points each), with skin lesions, CNS involvement, vascular manifestations, and positive pathergy each contributing 1 point. A score of 4 or more classifies the patient as having Behçet's disease. The ICBD improves sensitivity in Western and Japanese patients, where pathergy is less prevalent, and explicitly includes neurological and vascular manifestations — which the ISG 1990 criteria omitted — as scoring items. A multicenter validation study across 27 countries demonstrated sensitivity of 94.8% and specificity of 90.5% for the ICBD 2014.

Laboratory workup supports the clinical diagnosis but does not confirm it. Complete blood count may show leukocytosis and neutrophilia during active flares. ESR and CRP are elevated with active disease. Crucially, ANA, ANCA, anti-dsDNA, anti-SSA, anti-SSB, rheumatoid factor, and anti-CCP are all negative — their positivity should prompt reconsideration of the diagnosis. HLA-B51 typing supports the diagnosis in ambiguous cases (particularly in Western patients where the prior probability is low) but is neither required nor sufficient — many HLA-B51-positive individuals never develop Behçet's, and a substantial minority of patients with clear Behçet's disease are HLA-B51-negative.

Ophthalmological evaluation is mandatory in all suspected Behçet's patients, regardless of visual symptoms. Posterior uveitis and retinal vasculitis may be asymptomatic in early stages. Slit-lamp examination assesses anterior chamber inflammation and hypopyon. Dilated fundus examination and fluorescein angiography evaluate retinal vasculitis, optic disc involvement, and neovascularization.

Neuroimaging (MRI brain with and without gadolinium, plus MR venography) is indicated when neurological symptoms are present. Parenchymal neuro-Behçet produces T2/FLAIR hyperintensities in the brainstem and diencephalon on MRI, with gadolinium enhancement during active lesions. MR venography identifies dural venous sinus thrombosis. Lumbar puncture in acute neuro-Behçet typically shows a pleocytosis with elevated protein — findings that must be distinguished from infectious meningitis by appropriate cultures and viral PCR.

Colonoscopy is performed when GI symptoms (abdominal pain, diarrhea, GI bleeding) are present. The characteristic punched-out, well-demarcated round ulcers at the ileocecal junction, with a normal-appearing surrounding mucosa, are the endoscopic signature of intestinal Behçet's and help distinguish it from Crohn's disease on colonoscopy.

Vascular imaging (CT angiography or MR angiography) of the chest and abdomen is indicated when pulmonary symptoms (particularly hemoptysis) or abdominal aneurysm is suspected. The combination of venous thrombosis and arterial aneurysm in a young patient from an endemic region is essentially pathognomonic of Behçet's disease.

Back to Table of Contents

Treatment

Colchicine (1–2 mg/day) is the standard initial treatment for mucocutaneous disease and arthritis. It reduces the frequency and severity of oral ulcers, genital ulcers, erythema nodosum, and articular flares. Multiple randomized controlled trials support its efficacy for these manifestations. It is well-tolerated and used long-term for maintenance. It does not adequately control ocular, neurological, or vascular disease.

Apremilast (Otezla, 30 mg twice daily), a phosphodiesterase-4 inhibitor that suppresses proinflammatory cytokines including TNF-α, IL-17, and IL-23, received FDA approval in 2021 specifically for oral ulcers in Behçet's disease — making it the first FDA-approved drug for any indication related to Behçet's. Approval was based on the RELIEF trial published by Hatemi and colleagues in the New England Journal of Medicine in 2019, which demonstrated that apremilast significantly reduced oral ulcer count, pain scores, and overall disease activity compared with placebo in a randomized, double-blind, 12-week study. Apremilast represents an important advance for patients with predominantly mucocutaneous disease who have inadequate colchicine response or cannot tolerate it.

Topical corticosteroids (triamcinolone acetonide paste or clobetasol gel) are useful for managing individual oral and genital ulcers, reducing local inflammation, and decreasing pain. They are used as adjuncts rather than disease-modifying agents.

Azathioprine (2.5 mg/kg/day) was established as effective for ocular Behçet's disease by the landmark randomized controlled trial by Yazici and colleagues published in the New England Journal of Medicine in 1990 — the first RCT in Behçet's disease. Azathioprine significantly reduced the incidence of new eye lesions, visual loss, and the development of new systemic manifestations compared with placebo over a two-year period. It remains a standard maintenance agent for ocular and systemic disease, also used for articular and mucocutaneous disease when colchicine is insufficient.

Cyclosporine (3–5 mg/kg/day) is effective for suppressing uveitis and reducing ocular flare frequency. However, it carries a specific risk of inducing or worsening CNS involvement in Behçet's disease, making it relatively contraindicated in patients with neurological disease or at significant neurological risk. Its use requires careful monitoring of renal function and blood pressure. Many centers reserve it for refractory ocular disease when TNF inhibitors are unavailable or contraindicated.

TNF-α inhibitors — infliximab (5 mg/kg IV) and adalimumab — have become the most powerful tools available for refractory Behçet's disease. They are highly effective for sight-threatening posterior uveitis, refractory mucocutaneous disease, GI involvement with deep ulcers or perforation risk, and arthritis. Multiple observational studies and registries have documented dramatic visual improvement and ulcer resolution with infliximab, including in patients who had failed azathioprine and cyclosporine. Infliximab has the fastest onset of action (days to weeks) and is preferred for acute, sight-threatening uveitis. Adalimumab is used for maintenance and in patients preferring subcutaneous self-injection.

IFN-α-2a (interferon alpha-2a, subcutaneous injection) has demonstrated efficacy for ocular disease, particularly posterior uveitis, in several prospective studies from European centers. It is considered an alternative to TNF inhibitors for refractory uveitis. Significant side effects (flu-like symptoms, depression, cytopenias) limit tolerability in some patients. Its use is more common in Germany and other European countries than in North America.

Thalidomide is effective for severe, refractory mucocutaneous disease — particularly large genital ulcers and persistent oral ulcers unresponsive to colchicine and topical therapy. Its significant teratogenicity (absolute contraindication in pregnancy) and risk of irreversible peripheral neuropathy severely limit its use, particularly in women of childbearing age. It requires stringent prescribing controls (REMS program in the USA).

Methotrexate and mycophenolate mofetil are used as steroid-sparing agents for CNS disease and for maintenance of remission in systemic disease. Cyclophosphamide combined with high-dose corticosteroids is reserved for severe parenchymal neuroBehçet or severe vascular disease refractory to standard agents.

Anticoagulation for venous thrombosis in Behçet's disease is controversial. Unlike thrombosis in antiphospholipid syndrome or hereditary thrombophilia, Behçet's venous thromboses are driven primarily by vessel wall inflammation, and the concurrent vasculitis — especially pulmonary arterial aneurysms — can cause catastrophic hemorrhage if anticoagulated. The current consensus favors immunosuppression as the primary treatment for venous thrombosis (with corticosteroids and/or azathioprine, cyclophosphamide for severe cases), with anticoagulation added cautiously after pulmonary aneurysms have been excluded by imaging.

There is currently no cure for Behçet's disease. The goals of management are reduction of flare frequency, prevention of irreversible organ damage (particularly blindness and neurological disability), and management of treatment-related toxicities. Multidisciplinary care involving rheumatology, ophthalmology, neurology, gastroenterology, and vascular surgery is optimal for patients with multiorgan disease.

Back to Table of Contents

Differential Diagnosis

Behçet's disease mimics several common and rare conditions, particularly in early disease when the full clinical picture has not yet evolved. The absence of a diagnostic biomarker makes this differential especially important.

Recurrent aphthous stomatitis is the most common condition confused with Behçet's at the time of initial presentation. Recurrent aphthous ulcers affect up to 20–25% of the general population. The critical distinction is that recurrent aphthous stomatitis is confined to the oral mucosa, has no systemic features, and is not associated with genital ulcers, ocular inflammation, or skin disease. In the absence of these extraoral manifestations, a diagnosis of Behçet's should not be made regardless of oral ulcer frequency.

Herpes simplex virus (HSV) infection causes orolabial and genital ulcers that may superficially mimic Behçet's. HSV ulcers are typically vesicular before ulcerating (Behçet's are never vesicular), cluster in dermatomal distributions, and can be confirmed by viral culture, PCR, or DFA testing of active lesions. Systemic features of HSV recurrence are minimal and self-limited.

Crohn's disease overlaps significantly with intestinal Behçet's — both cause ileocecal ulceration, perianal involvement, oral aphthous ulcers, erythema nodosum, and arthritis. The geographic distinction (Crohn's predominantly North European/North American; Behçet's predominantly Silk Road) is helpful but not definitive. Endoscopic morphology is the key differentiator: Behçet's produces round, discrete, punched-out ulcers at the ileocecal valve, while Crohn's produces linear, longitudinal ulcers, cobblestoning, skip lesions, and transmural granulomatous inflammation on biopsy.

Reactive arthritis (formerly Reiter's syndrome) — the triad of arthritis, urethritis/cervicitis, and conjunctivitis — can be confused with Behçet's. However, reactive arthritis is triggered by specific infections (Chlamydia, Salmonella, Yersinia), is HLA-B27-associated, produces conjunctivitis rather than uveitis, and lacks oral/genital aphthous ulcers. Keratoderma blennorrhagicum (palmoplantar pustules) in reactive arthritis may mimic Behçet's skin lesions.

Systemic lupus erythematosus (SLE) can present with oral ulcers, serositis, arthritis, and CNS involvement overlapping with Behçet's. ANA positivity (present in >95% of SLE), anti-dsDNA antibodies, complement consumption, and the malar rash pattern distinguish SLE. Behçet's is ANA-negative by definition.

Periodic fever syndromes — particularly Familial Mediterranean Fever (FMF) — are important in the differential, especially in the same geographic populations (Turkish, Armenian, Arab, Jewish patients). FMF causes recurrent febrile episodes with serositis (peritonitis, pleuritis, pericarditis), erysipelas-like skin lesions, and arthritis, but lacks the mucosal ulcers, ocular disease, and vascular manifestations of Behçet's. The MEFV gene mutation (pyrin) confirms FMF. Co-occurrence of FMF and Behçet's has been reported.

Other vasculitides — GPA (granulomatosis with polyangiitis), EGPA (eosinophilic granulomatosis with polyangiitis), and polyarteritis nodosa — overlap with Behçet's vascular manifestations. ANCA seropositivity, necrotizing granulomatous histology, sinus/nasal involvement (GPA), eosinophilia and asthma (EGPA), and medium vessel involvement without venous thrombosis distinguish these entities from Behçet's.

Sarcoidosis presents with bilateral hilar lymphadenopathy, uveitis, erythema nodosum, and arthritis — all shared with Behçet's. Non-caseating granulomas on biopsy, elevated serum ACE, and the absence of genital ulcers and pathergy distinguish sarcoidosis.

Back to Table of Contents

Prognosis and Monitoring

The prognosis of Behçet's disease is highly variable, ranging from predominantly mucocutaneous disease with minimal systemic impact to rapidly progressive multiorgan involvement with permanent disability. The organ systems affected determine prognosis more than any single laboratory value or genetic marker.

Mucocutaneous and articular disease carry a generally favorable prognosis. Oral and genital ulcers, though painful and recurrent, do not threaten organ function. Arthritis is non-erosive and does not cause permanent joint destruction. Skin manifestations, including erythema nodosum and pseudofolliculitis, resolve with treatment and leave no lasting damage. Patients with disease confined to these systems can expect a near-normal quality of life with appropriate treatment, though recurrent flares may significantly impact daily function and productivity.

Ocular disease is the most important determinant of disability in young patients. Without treatment, approximately 25% of patients with posterior uveitis and retinal vasculitis progress to legal blindness within five years of ocular disease onset. Early aggressive immunosuppression — azathioprine as a minimum, with rapid escalation to TNF inhibitors for posterior involvement — has substantially improved visual outcomes in the modern era. Patients with bilateral posterior uveitis, recurrent retinal vasculitis, or epiretinal membranes are at highest risk of irreversible visual loss and require the most intensive long-term surveillance and treatment.

Neurological disease carries the worst prognosis among Behçet's manifestations. Parenchymal neuro-Behçet — direct brain parenchymal inflammation — results in permanent neurological deficits in 40–50% of affected patients, including pyramidal weakness, cerebellar dysfunction, cognitive impairment, and behavioral change. Brainstem involvement is particularly ominous. Vascular neuro-Behçet (dural sinus thrombosis) has a better overall prognosis, with recovery possible when treated promptly with immunosuppression and anticoagulation. The cumulative disability burden from neurological disease is the leading cause of work incapacity and significantly reduced life expectancy in the most severely affected patients.

Vascular disease is potentially fatal. Pulmonary artery aneurysm rupture presents with massive hemoptysis and carries a high acute mortality risk. Arterial aneurysms at other sites (peripheral, visceral) may rupture or thrombose. Budd-Chiari syndrome from hepatic vein thrombosis can cause rapidly progressive liver failure. These vascular complications, though uncommon, are the dominant cause of Behçet's-related mortality and demand prompt aggressive treatment — typically high-dose corticosteroids with cyclophosphamide, followed by maintenance immunosuppression. Embolization or surgical repair may be required for accessible aneurysms.

Disease course over time often shows a "burning out" phenomenon — many patients experience decreasing flare frequency and severity after the fifth decade of life, particularly for mucocutaneous manifestations. This natural attenuation is well-recognized clinically and pathophysiologically reflects age-associated immune senescence. However, organ damage accrued during earlier, more active disease phases — visual loss, neurological deficits, fibrotic vascular changes — is irreversible. Young males in endemic regions carry the highest risk of severe disease and the greatest urgency for early aggressive treatment.

Monitoring in clinical practice includes regular ophthalmological review (at minimum every 3–6 months with active ocular disease), periodic MRI brain for patients with neurological history, interval vascular imaging for those with known aneurysms, and organ-specific laboratory testing. There is no validated composite disease activity index as widely accepted as the BASDAI (for ankylosing spondylitis) or SLEDAI (for lupus) for Behçet's, though the Behçet's Disease Current Activity Form (BDCAF) is used in research and specialty centers to standardize longitudinal assessment.

Back to Table of Contents

Recent Research and Advances

The RELIEF trial (Hatemi et al., 2019, N Engl J Med) established apremilast as the first FDA-approved treatment for oral ulcers in Behçet's disease and demonstrated the efficacy of targeted phosphodiesterase-4 inhibition in Behçet's mucocutaneous disease. The 12-week randomized, double-blind, placebo-controlled trial showed statistically and clinically significant reductions in oral ulcer number, pain, and overall disease activity (BDCAF score). Long-term open-label extension data suggest durable benefit with continued treatment. This approval represented a major regulatory milestone — acknowledging Behçet's disease as a distinct therapeutic target and opening the path for further targeted drug development.

Biologics beyond TNF inhibitors are under investigation. Secukinumab (anti-IL-17A) and ixekizumab are being studied given the established role of the Th17/IL-17 axis in Behçet's pathogenesis. Early-phase studies and case series suggest potential efficacy for mucocutaneous and articular disease. JAK inhibitors (tofacitinib, upadacitinib) are being explored based on their broad cytokine suppression profile, with early signals of benefit in refractory cases. These developments reflect the broader trend toward molecularly targeted immunotherapy across inflammatory arthropathies.

Gut microbiome dysbiosis has emerged as an area of active investigation. Several studies have identified compositional differences in the gut microbiome of Behçet's patients compared to healthy controls, with altered Firmicutes/Bacteroidetes ratios and reduced microbial diversity correlating with disease activity and mucosal ulceration. The ileocecal predilection of intestinal Behçet's may reflect local interaction between luminal bacteria, epithelial integrity, and mucosal immune activation. Whether microbiome modulation (through probiotics, fecal microbiota transplantation, or dietary intervention) can modify disease course is being evaluated.

Revised ICBD 2014 criteria have improved diagnostic sensitivity in Western patients, where pathergy is less prevalent. The elimination of pathergy as a mandatory criterion (it contributes only one point in ICBD 2014) and the explicit inclusion of neurological and vascular disease as scoring items have expanded the diagnostic reach in populations with atypical presentations. Multi-center registry data from the EuroFever/PRINTO registry and North American Behçet's consortium are providing real-world data on treatment patterns, outcomes, and long-term prognosis in Western cohorts.

Visual outcomes with early anti-TNF therapy have been dramatically improved over historical natural history data. Registry studies from Turkish and Spanish centers show that patients started on infliximab within the first year of ocular disease onset have significantly lower rates of visual loss and lower cumulative uveitis relapse rates compared with historical cohorts treated with azathioprine and cyclosporine alone. These findings are driving recommendations for earlier, more aggressive use of TNF inhibitors for posterior uveitis, rather than reserving them as a "last resort" after multiple agent failures.

Genetic and mechanistic research continues to refine the HLA-B51 story. Structural studies of HLA-B*51:01 have identified a unique peptide-binding groove configuration that may preferentially present specific microbial or self-peptides to CD8+ T cells. GWAS in large multinational cohorts have confirmed additional non-HLA susceptibility loci (ERAP1, IL-10, IL-23R) and are beginning to identify gene-gene interactions that modulate risk. Understanding these genetic determinants may ultimately point toward the specific antigen(s) driving the autoreactive response — the most fundamental unresolved question in Behçet's pathobiology.

Back to Table of Contents

References

  1. Behçet H. Über rezidivierende, aphthöse, durch ein Virus verursachte Geschwüre am Mund, am Auge und an den Genitalien. Dermatologische Wochenschrift. 1937;105:1152–1157. [Historical reference]
  2. Criteria for diagnosis of Behçet's disease. International Study Group for Behçet's Disease. Lancet. 1990;335(8697):1078–1080. PMID 1970380
  3. Davatchi F, et al. The International Criteria for Behçet's Disease (ICBD): a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol. 2014;28(3):338–347. PMID 23441863
  4. Yazici H, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med. 1990;322(5):281–285. PMID 2404204
  5. Hatemi G, et al. Apremilast for Behçet's syndrome — a phase 2, placebo-controlled study. N Engl J Med. 2015;372(16):1510–1518. PMID 25901427
  6. Hatemi G, et al. Trial of Apremilast for Oral Ulcers in Behçet's Syndrome. N Engl J Med. 2019;381(18):1717–1726. PMID 31665579
  7. Kalra S, et al. Behçet's disease: a comprehensive review of clinical features, pathophysiology, and management. Rheum Dis Clin North Am. 2017;43(3):371–382. PMID 28711140
  8. Seyahi E. Behçet's disease: how to diagnose and treat vascular involvement. Best Pract Res Clin Rheumatol. 2016;30(2):279–295. PMID 27886802
  9. Yurdakul S, et al. Behçet syndrome. Best Pract Res Clin Rheumatol. 2008;22(5):793–809. PMID 19028370
  10. Hisamatsu T, et al. Criteria and pathophysiology of intestinal Behçet's disease. J Gastroenterol. 2014;49(1):36–42. PMID 24213131
  11. Nair JR, et al. Behçet's disease. BMJ. 2017;357:j1795. PMID 28512095
  12. Scherrer MAR, et al. Behçet's disease: review with emphasis on dermatological aspects. An Bras Dermatol. 2017;92(4):452–464. PMID 28954098

Back to Table of Contents

Connections

Back to Table of Contents